01200-X/asset/1ec2c191-5a64-4856-842f-bfa65a8fabc6/main.assets/gr2.jpg)
surmount-2 tirzepatide type 2 diabetes weight loss results 2023 2024 once weekly for the treatment of obesity in people with (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial Tirzepatide vs semaglutide: A new
Description
If you inject tirzepatide in the stomach , the initial onset of side effects may begin slightly sooner, within 1 to 2 hours rather than 2 to 3 hours
Joint pain decreases as load diminishes
A microdose, by contrast, provides a modest metabolic nudge without obliterating appetite
Notably, these symptoms were not reported during tirzepatide's clinical trials
Your appetite dropped
Similarly, semaglutide was administered via sub-cutaneous weekly injections with no restrictions on day or time of day (again, consistency of day and time were advised)
